Markets

Norsk Hydro’s Q3 2025 adjusted EBITDA decreased to NOK 5,996m due to lower alumina prices and a stronger NOK, while free cash flow remained strong at NOK 2.2bn, and net debt reduced to NOK 13.6bn. The company launched a cost reduction program targeting NOK 1bn annual savings from 2026 and secured a power agreement for Alouette through 2045. A Rotterdam court dismissed all 2021 claims against Hydro. They also divested Corvus Energy for USD 30m.

Linear Minerals Corp. shareholders approved a strategic restructuring at their annual meeting, including the spin-out of the Pontax West Lithium Property into a new subsidiary, Westlinear Minerals Corp. (Spinco). Shareholders will receive 1 Spinco share for every 10 Linear shares. Gurminder Sangha and four other directors were re-elected. The arrangement is subject to court and exchange approvals, and the Share Distribution Record Date will be announced later. This move aims to enhance focus and growth potential for both entities.

GSK’s *Blenrep* (belantamab mafodotin-blmf) has received FDA approval for relapsed or refractory multiple myeloma patients after at least two prior therapies. Backed by the DREAMM-7 trial, *Blenrep* combined with bortezomib and dexamethasone showed a 51% reduction in death risk and tripled progression-free survival compared to a daratumumab-based triplet. *Blenrep* is the only anti-BCMA agent accessible in community settings, with a streamlined REMS program. GSK is actively developing *Blenrep* for earlier lines of treatment, with ongoing trials and data expected in the coming years.

Provident Financial Holdings (NASDAQ: PROV) announced a quarterly cash dividend of $0.14 per share. Shareholders of record on November 13, 2025, will receive the dividend, payable on December 4, 2025. The company’s decision reflects confidence in its financial position and commitment to shareholder returns.

Archrock, Inc. (NYSE: AROC) declared a quarterly cash dividend of $0.145 per common share, payable May 15, 2024, to holders of record on May 7, 2024. This reflects Archrock’s financial stability and commitment to shareholder value amid evolving energy market dynamics. The company’s focus on efficient operations, advanced compression technologies, and sustainable solutions, including exploring alternative power sources, supports its long-term business model and resilience in a capital-intensive industry. Investors are monitoring Archrock’s strategies to balance returns with innovation and sustainability investments.

Ionis Pharmaceuticals, a leader in RNA-targeted therapeutics, debuted as a top employer in *Science* magazine’s survey, ranking second. The company excelled in innovation, values alignment, employee loyalty, and respect. This recognition coincides with Ionis’ progress in RNA therapeutics, developing antisense oligonucleotides for diseases like spinal muscular atrophy. CEO Brett Monia credits the company’s success to its people and culture, while Eric Swayze emphasizes their patient-centric approach. Ionis faces increasing competition in the RNA therapy market but aims to maintain its leadership through continued innovation and talent retention.

Alcon and STAAR Surgical announced the postponement of STAAR’s Special Meeting of Stockholders regarding their proposed merger. Originally scheduled for October 23, 2025, it’s now set for November 6, 2025. The record date for voting eligibility remains September 12, 2025. The merger aims to strengthen Alcon’s refractive surgery market position through STAAR’s ICL technology. Analysts suggest regulatory reviews and due diligence contributed to the delay. The combined entity anticipates innovation in intraocular lens technology but faces integration challenges and market competition.

Jeep launched a social media campaign featuring comedian Iliza Shlesinger to promote the 2026 Grand Wagoneer. The “Family SUV” campaign, created with Highdive, humorously highlights the vehicle’s spaciousness, comfort, and safety features. Shlesinger parodies traditional vehicle reveals in the video, now on YouTube, with shorter clips on other platforms. The 2026 Grand Wagoneer, starting under $65,000, aims for family-friendliness with added value.

VSee Health (NASDAQ:VSEE) announced on October 23, 2025, record revenue growth and the elimination of over $5 million in legacy SPAC debt. This strengthens the company’s balance sheet, boosts creditor confidence, and aids NASDAQ listing compliance. Management highlighted shareholder support and views this as positioning VSee Health for sustained long-term growth. The company aims to capitalize on the telehealth sector’s expansion with its scalable, API-driven platform.

Ermenegildo Zegna N.V. reported a 2.3% YoY decrease in revenue for 9M 2025, totaling €1,325.9 million. Q3 2025 revenues, however, grew slightly by 0.2% YoY to €398.2 million, with a 3.6% organic increase. DTC channel sales rose 4.5% YoY (9.1% organic), while wholesale declined. Zegna brand led the growth, with Thom Browne experiencing a decline. The Americas region showed strong organic growth. The company anticipates a challenging environment due to consumer demand and currency fluctuations.